Tuesday, April 23, 2019 5:10:51 AM
It is interesting because basically it states that adjusted to socioeconomic and insurance status , survival in the white group and black group is more or less the same, while some minor differences (in stage occurrences, etc) can be observed.
This means that the large difference in OS that we see in SEER data between blacks and whites in the US is mainly due to socioeconomic / ability to pay for insurance reasons.
Other fact (Many links can be found on this topic) is that HPV related oscc has mainly developed in western countries, while is less spread in poorer countries or even countries like Italy :
hpv Italy
hpv Ghana
My personal conviction from all that I have read is that the real progresses in OS observed in North America is due mainly to the spread of the HPV related oscc in the white male population, while tobacco/alcool related oscc were occurrences were going down with healthier habits.
Therefore, the oscc observed in most of the sites of the study _ from which 62 out of 101 are in developing countries please see the list here :
List of dev. countries sites
_ are mostly not HPV related and mostly affecting a population which has low socioeconomic standards and poor ability to pay for insurances.
We have seen how disastrous survival was in Bulgaria : heavy smokers and drinkers, likely little HPV prevalence, less private insurances.
I do therefore believe that observed OS in the clinical trial treated by SOC only is far below the observed survival in North American statistics and closer from what Cel SCI states as an unchanged survival of near 50% OS @ Y5 in absolute numbers
Recent CVM News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2024 09:30:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2024 01:30:30 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/08/2024 05:15:11 AM
- U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025 • Business Wire • 11/07/2024 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/30/2024 09:21:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/25/2024 09:17:48 PM
- FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients • Business Wire • 10/22/2024 01:15:00 PM
- Form AW - Amendment Withdrawal Request • Edgar (US Regulatory) • 10/10/2024 08:05:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 01:13:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 01:05:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 12:58:09 PM
- CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer • Business Wire • 10/01/2024 10:00:00 AM
- CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation • Business Wire • 09/16/2024 11:30:00 AM
- CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress • Business Wire • 09/10/2024 01:32:00 PM
- The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance • Business Wire • 09/04/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/30/2024 08:32:13 PM
- CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results • Business Wire • 08/15/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:27:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:16:11 PM
- CEL-SCI Announces Closing of $10.8 Million Offering • Business Wire • 07/29/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/29/2024 11:00:58 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 09:27:40 PM
- CEL-SCI Announces Pricing of $10.8 Million Offering • Business Wire • 07/26/2024 03:52:00 PM
FEATURED Are we about to see a comeback? Steakholder Foods Charges Forward with New Commitments from Multiple International Players as it Transitions to Revenue Generation • Nov 18, 2024 11:56 AM
FEATURED North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • Nov 18, 2024 9:00 AM
One World Products Sets New Standards in Sustainability With Strategic Hemp Innovations • OWPC • Nov 18, 2024 7:54 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM